Reduced-Dose Radiotherapy + Temozolomide for Glioblastoma

This trial explores whether a reduced dose of radiation, combined with the standard drug temozolomide, can slow the progression of glioblastoma, an aggressive brain tumor. Participants will receive a new form of radiotherapy called pulsed reduced dose radiotherapy (pRDR), which uses lower doses in pulses, alongside chemotherapy. This approach may suit those recently diagnosed with glioblastoma who have undergone surgery and are scheduled for radiation and chemotherapy. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications, but it does exclude those who have received other antitumor therapies before enrolling. It's best to discuss your specific medications with the trial team.

Research has shown that pulsed reduced dose radiotherapy (pRDR) is generally well-tolerated. A large review found low rates of serious side effects, specifically grade 3 toxicity, in patients with recurring aggressive brain tumors, suggesting it is relatively safe for those receiving this treatment.

The trial also uses temozolomide (TMZ), a chemotherapy drug. Studies have shown that temozolomide is safe for older adults and can extend their lives when used after radiation therapy. It has been effective in treating glioblastoma, a type of brain cancer.

Pulsed reduced dose-rate radiotherapy (pRDR) is unique because it offers a new approach to treating glioblastoma by combining reduced-dose radiotherapy with temozolomide, a chemotherapy drug. Unlike traditional radiotherapy, which can be intense and taxing on the body, pRDR uses lower doses delivered in pulses, potentially reducing side effects while still fighting cancer cells effectively. Researchers are excited about this treatment because it aims to maintain the effectiveness of standard treatments while improving the quality of life for patients by minimizing harmful side effects.

Research has shown that pulsed reduced dose radiotherapy (pRDR) can help patients with glioblastoma live longer. Studies have found that pRDR, especially when combined with bevacizumab (a cancer-fighting drug), can significantly extend the time patients live without disease progression and increase overall survival time. In one study, patients lived a median of about 12.6 months after receiving pRDR treatment.